

Risk profile (SRRI) <sup>1)</sup>

1	2	3	4	5	6	7
---	---	---	---	---	---	---

## CS (Lux) Global Biotech Innovators Equity Fund

a subfund of CS Investment Funds 5 - Class UBH EUR

### Investment policy

This sector-based equity fund globally invests in stocks of biotechnology companies to achieve long-term capital appreciation while maintaining an adequate distribution of risks. It offers access to one of the fastest-growing segments of the health sector, and opportunity to participate in growth in value tied to clinical progress of innovative products from early stage to those ready to be brought to market. The fund invests in numerous therapeutics areas, as well as diagnosis and preventative treatments. The portfolio is not constrained either in terms of geography or by market capitalization. The NASDAQ Biotechnology TR serves as the benchmark.

### Fund facts


<b>Fund manager</b>	Credit Suisse AM Thematic Equity Team
<b>Fund manager since</b>	15.12.2016
<b>Location</b>	Zurich
<b>Fund domicile</b>	Luxembourg
<b>Fund currency</b>	USD
<b>Close of financial year</b>	30. Sep
<b>Total net assets (in millions)</b>	148.48
<b>Inception date of share class</b>	27.02.2015
<b>Management fee in % p.a.</b>	1.15
<b>TER (as of 30.09.2016) in %</b>	1.49
<b>Benchmark (BM)</b>	No Benchmark
<b>Swinging single pricing (SSP) <sup>3)</sup></b>	Yes
<b>Unit Class</b>	Category UBH (capital growth)
<b>Unit class currency</b>	EUR
<b>ISIN number</b>	LU1144413926
<b>Bloomberg ticker</b>	CSBUBHE LX
<b>Net Asset Value</b>	98.28
<b>Redemptions</b>	Daily
<b>Sales registration:</b>	Austria, Chile, France, Germany, Italy, Liechtenstein, Luxembourg, Singapore, Spain, Switzerland

<sup>3)</sup> For more details, please refer to the relevant chapter "Net Asset Value" of the Fund's prospectus.

### Fund Statistics

	3 years	5 years
Annualised volatility in %	25.13	23.96
Information ratio	-	-
Tracking Error (Ex post)	-	-
Beta	-	-

### Net performance in EUR (rebased to 100) and yearly performance <sup>2)</sup>



Source: Lipper, a Thomson Reuters company

The document reflects performance of the shareclass CS (Lux) Global Biotech Innovators Equity Fund UBH EUR extended with track record of already existing, equivalent by distribution type and valuation currency retail shareclass.


### Net performance in EUR <sup>2)</sup>

	1 month	3 months	YTD	1 year	3 years	5 years
Fund	2.03	-2.87	26.54	21.57	10.43	126.24


### Sectors in %

	Fund
Biotechnology	72.11
Life Sciences Tools & Services	8.44
Health Care Equipment	8.13
Pharmaceuticals	7.27
Health Care Services	3.09
Cash/Cash Equivalents	0.96

### Currencies in %



### Countries in %



### Significant Transactions

Purchases	Sales
-	-

### Number of holdings

Fund	70
------	----

### Top 10 holdings in %

Biogen	3.26
Amgen	3.14
Biomarin Pharmaceutical	3.07
Gilead Sciences	3.03
Incyte	3.00
Teladoc	3.00
Celgene	2.99
Illumina	2.95
Vertex Pharma	2.92
Alnylam Pharmaceuticals	2.72
<b>Total</b>	<b>30.08</b>

<sup>1)</sup> The calculation of the risk indicator is based on the CESR/10-673 Directive. The risk indicator is based on historic and partly simulated data; it cannot be used to predict future developments. The classification of the Fund may change in future and does not represent a guarantee. A classification into category 1 is not a risk-free investment either.

<sup>2)</sup> Historical performance indications and financial market scenarios are not reliable indicators of future performance. The performance data do not take into account the commissions and costs incurred on the issue and redemption of fund units.

The disclaimer mentioned at the end of this document also applies to this page.

## Contact

**CREDIT SUISSE AG**  
**Sucursal en España**  
**Calle Ayala 42**  
**28001 Madrid/Spain**  
**Tel +34 91 791 60 00 Fax +34 91 791 60 10**

This document has been prepared by Credit Suisse AG and/or one of its affiliates (hereafter "CS") with the greatest of care and to the best of its knowledge and belief. However, CS provides no guarantee with regard to its content and completeness, and does not accept any liability for losses which might arise from making use of this information. The opinions expressed in this document are those of CS at the time of writing and are subject to change at any time without notice. Unless stated otherwise, all figures are unaudited. This document is provided for information purposes only and is for the exclusive use of the recipient. It does not constitute an offer or recommendation to buy or sell financial instruments or banking services and does not release the recipient from exercising his/her own judgment. In particular, the recipient is advised to check that the information provided is in line with his/her own circumstances with regard to any legal, regulatory, tax or other consequence, with the help of a professional advisor if necessary. This document may not be reproduced in part or in full without the written permission of CS. Neither this document nor any copy thereof may be sent, taken into or distributed in the United States or to any US person (within the meaning of Regulation S of the US Securities Act of 1993 in its current form). It is not intended for persons who, due to their nationality or place of residence, are not permitted access to such information under local law. Every investment involves risk, especially with regard to fluctuations in value and return. Investments in foreign currencies entail the additional risk that the foreign currency might lose value against the investor's reference currency. Neither historical nor future performance indications and financial market scenarios are guarantee for current or future performance. Performance indicators do not take account of commissions levied at subscription and/or redemption. Furthermore, no guarantee can be given that the benchmark performance will be reached or exceeded. In connection with the transactions in the products or services mentioned herein, Credit Suisse AG may pay to or receive from third parties one-time or recurring remunerations as part of its compensation. You may request further information from your financial advisor. Potential conflicts of interest cannot be excluded. This document qualifies as marketing material that has been published for advertising purposes. It should not be read as an independent financial or investment analysis. It does not constitute financial advising or any other regulated financial service. The investment funds' mentioned in this publication have been established under Luxembourg law as undertakings for collective investment in transferable securities (UCITS) and are subject to EU Directive 2009/65/EC, as amended. Subscriptions will only be valid on the basis of the current sales prospectus, simplified prospectus or key investor information document (if any) and the most recent annual report (or semi-annual report, if the latter is more recent), the latest financial report published and the fund's annual trading report in Spain registered with the National Securities Market Commission. These, along with the rest of the fund's instruments of incorporation, may be obtained free of charge from Credit Suisse AG, Spain, at its registered office at Calle Ayala 42, 28001 Madrid, Spain. Investors should carefully read and analyze the content of the aforementioned documents and should seek professional advising if necessary prior to making any investment in this product. This material is distributed in Spain by Credit Suisse AG, Spain, an entity registered with the National Securities Market Commission as a fund distributor.

Copyright © 2017 Credit Suisse Group AG and/or its affiliates. All rights reserved.